The Health Ministry of India is reportedly considering a ban on cough syrups prescribed to children under two years and discouraging their use for those under five years. This proposal is part of the draft National Formulary of India (NFI) 2026, which was released by the Indian Pharmacopoeia Commission. The draft aims to standardize drug information and improve safety following a series of contamination-linked deaths in 2025 due to toxic solvents like diethylene glycol (DEG) and ethylene glycol (EG) found in some cough syrups. The draft explicitly states that cough and cold medications should not be prescribed to children under two, and emphasizes the need for careful clinical evaluation for those under five. Pharmaceutical companies will be required to conduct rigorous testing of their products to ensure safety, with public health experts supporting the initiative as cough syrups provide limited therapeutic benefits for infants. The Indian Drugs Manufacturers Association is currently reviewing the draft for feedback.